Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese zucker rats as determined by microarray analysis

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 6, 2008, Pages 315-325

  Song, J ^a   Liu, H ^b   Ressom, H W ^c   Tiwari, S ^a   Ecelbarger, C M ^a,d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Obesity; PPAR agonists; Renal; Thiazolidinediones; Type II diabetes

Indexed keywords

ACYL COENZYME A DESATURASE; AQUAPORIN 3; CD36 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; EPITHELIAL SODIUM CHANNEL; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; GLUCOSE; HYDROLASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN NACL COTRANSPORTER; REGULATOR PROTEIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CHAIN; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE PROBE; GENOME ANALYSIS; KIDNEY FUNCTION; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; RAT; UPREGULATION; ZUCKER RAT;

ANIMALS; CHROMOSOME MAPPING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOME; KIDNEY; MALE; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, ZUCKER; STEAROYL-COA DESATURASE; THIAZOLIDINEDIONES;

EID: 46749142478     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1042429     Document Type: Article

References (51)

1. Affymetrix. Data Sheet: Gene Chip Rat Genome 230 Arrays 2005
2. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999; 21: 76-83
3. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996; 28: 1047-1054
4. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327
5. Becker M, Umrani D, Lokhandwala MF, Hussain T. Increased renal angiotensin II AT1 receptor function in obese Zucker rat. Clin Exp Hypertens 2003; 25: 35-47
6. Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs 2006; 7: 891-897
7. Bickel CA, Verbalis JG, Knepper MA, Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats. Am J Physiol Renal Physiol 2001; 281: F639-648
8. Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N. Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol 1997; 272: F405-409
9. Chen L, Yang B, MacNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK. GI262570, a peroxisome proliferator-activated receptor (gamma) agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 2005; 312: 718-725
10. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192
11. Deak F, Wagener R, Kiss I, Paulsson M. The matrilins: a novel family of oligomeric extracellular matrix proteins. Matrix Biol 1999; 18: 55-64
12. Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol 2000; 279: F46-53
13. Ecelbarger CA, Knepper MA, Verbalis JG. Increased abundance of distal sodium transporters in rat kidney during vasopressin escape. J Am Soc Nephrol 2001; 12: 207-217
14. Erdely A, Freshour G, Maddox DA, Olson JL, Samsell L, Baylis C. Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 2004; 47: 1672-1676
15. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151-163
16. Fujiwara K, Hayashi K, Matsuda H, Kubota E, Honda M, Ozawa Y, Saruta T. Altered pressure-natriuresis in obese Zucker rats. Hypertension 1999; 33: 1470-1475
17. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866
18. Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-1022
19. Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001; 281: F1036-1046
20. Harker CT, O'Donnell MP, Kasiske BL, Keane WF, Katz SA. The renin-angiotensin system in the type II diabetic obese Zucker rat. J Am Soc Nephrol 1993; 4: 1354-1361
21. Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159: 1811
22. Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, Brown J. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. Faseb J 2003; 17: 1966-1968
23. Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002; 22: 1-23
24. Huang X, Birk DE, Goetinck PF. Mice lacking matrilin-1 (cartilage matrix protein) have alterations in type II collagen fibrillogenesis and fibril organization. Dev Dyn 1999; 216: 434-441
25. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003; 46: 288-290
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264
27. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032
28. Jezek P, Garlid KD. Mammalian mitochondrial uncoupling proteins. Int J Biochem Cell Biol 1998; 30: 1163-1168
29. Kaestner KH, Ntambi JM, Kelly Jr TJ, Lane MD. Differentiation- induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase. J Biol Chem 1989; 264: 14755-14761
30. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol 2005; 289: F442-450
31. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 1998; 95: 14552-14557
32. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956
33. Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels 2001; 7: 249-258
34. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910
35. Markovich D, Aronson PS. Specificity and regulation of renal sulfate transporters. Annu Rev Physiol 2006
36. Martens FM, Visseren FL, Lemay J, Koning EJ de, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480
37. Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 1999; 104: R19-23
38. Miyazaki M, Ntambi JM. Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 113-121
39. Riazi S, Khan O, Hu X, Ecelbarger C. Aldosterone infusion with high-NaCl diet increases blood pressure in obese but not lean Zucker rats. Am J Physiol Renal Physiol 2006
40. Riazi S, Khan O, Tiwari S, Hu X, Ecelbarger CA. Rosiglitazone Regulates ENaC and Na-K-2Cl Cotransporter (NKCC(2)) Abundance in the Obese Zucker Rat. Am J Nephrol 2006; 26: 245-257
41. Rocchi S, Auwerx J. Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann Med 1999; 31: 342-351
42. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308: 426-433
43. Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications 2002; 16: 108-114
44. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 123-124
45. Tiwari S, Blasi ER, Hu X, Heyen J, Ecelbarger CA. Blood pressure, ENaC, and sgk-1 regulation in Sprague-Dawley rats after short-term administration of high-dose PPAR agonists. J Am Soc Nephrol 2005; 165: 566A (Abstract)
46. Tiwari S, Packer RK, Hu X, Sugimura Y, Verbalis JG, Ecelbarger CA. Increased renal {alpha}-ENaC and NCC abundance and elevated blood pressure are independent of hyperaldosteronism in vasopressin escape. Am J Physiol Renal Physiol 2006
47. Zwieten PA Van, Kam KL, Pijl AJ, Hendriks MG, Beenen OH, Pfaffendorf M. Hypertensive diabetic rats in pharmacological studies. Pharmacol Res 1996; 33: 95-105
48. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453
49. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47: 810-814
50. Xu ZG, Lanting L, Vaziri ND, Li Z, Sepassi L, Rodriguez-Iturbe B, Natarajan R. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 2005; 111: 1962-1969
51. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius 3rd FC, Schnermann JB, Briggs JP. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999; 277: F966-973